Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/57947
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
GENOME-BASED SURVEY OF THE SARS-COV-2 BF. 7 VARIANT FROM ASIA
Autor
Afiliación
Department of Biomedical Sciences. University of Sassari. Sassari, Italy
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil/Sciences and Technologies for Sustainable Development and One Health. University of Campus Bio‐Medico. Rome, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Azienza Ospedaliera Universitaria. Sassari, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy/Unit of Gastroenterology. Department of Medicine. University Campus Bio‐Medico of Rome. Rome, Italy
Sciences and Technologies for Sustainable Development and One Health. University of Campus Bio‐Medico. Rome, Italy
National HIV/AIDS Research Center. Rome, Italy Istituto Superiore di Sanità. Rome, Italy
Department GEPLI. Libera Università Ss Maria Assunta. Rome, Italy
Department of Biochemical Sciences“A. Rossi Fanelli”. Sapienza Università di Roma. Rome, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil/Sciences and Technologies for Sustainable Development and One Health. University of Campus Bio‐Medico. Rome, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Veterinary Medicine. University of Sassari. Sassari, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy/Azienza Ospedaliera Universitaria. Sassari, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy/Unit of Gastroenterology. Department of Medicine. University Campus Bio‐Medico of Rome. Rome, Italy
Sciences and Technologies for Sustainable Development and One Health. University of Campus Bio‐Medico. Rome, Italy
National HIV/AIDS Research Center. Rome, Italy Istituto Superiore di Sanità. Rome, Italy
Department GEPLI. Libera Università Ss Maria Assunta. Rome, Italy
Department of Biochemical Sciences“A. Rossi Fanelli”. Sapienza Università di Roma. Rome, Italy
Department of Biomedical Sciences. University of Sassari. Sassari, Italy
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio‐Medico of Rome. Rome, Italy
Resumen en ingles
The SARS-CoV-2 BF.7 variant represents one of the most recent subvariant under monitoring. At the beginning of the 2023 it caused several concerns especially in Asia because of a resurge in COVID-19 cases. Here we perform a genome-based integrative approach on SARS-CoV-2 BF.7 to shed light on this emerging lineage and produce some consideration on its real dangerousness. Both genetic and structural data suggest that this new variant currently does not show evidence of an high expansion capability. It is very common in Asia, but it appears less virulent than other Omicron variants as proved by its relatively low evolutionary rate (5.62 × 10−4 subs/sites/years). The last plateau has been reached around December 14, 2022 and then the genetic variability, and thus the viral population size, no longer increased. As already seen for several previous variants, the features that may be theoretically related to advantages are due to genetic drift that allows to the virus a constant adaptability to the host, but is not strictly connected to a fitness advantage. These results have further pointed that the genome-based monitoring must continue uninterruptedly to be prepared and well documented on the real situation.
Compartir